series-a
Stage
1
Investors
About
Axon Therapies develops a minimally invasive, implant-free catheter procedure called Splanchnic Ablation for Volume Management (SAVM) that targets the greater splanchnic nerve to reduce sympathetic nervous system activity and alleviate symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Explore Axon Therapies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.